New oral anticoagulants in atrial fibrillation
Article Sidebar
Main Article Content
Abstract
Atrial fibrillation is the most common sustained arrhythmia in adults. Its presence is associated with clinically relevant events such as: cerebrovascular accident, transient ischemic attack and systemic embolism. Anticoagulation is an effective action against systemic embolism. However, bleeding is a main risk of anticoagulation. Historically the most widely used anticoagulants were the vitamin K antagonists (warfarin, acenocoumarol). These drugs have many difficulties for chronic use (drug and dietary interactions, narrow therapeutic range). In recent years emerged as a therapeutic alternative in this group of patients the new anticoagulants. In this article we describe the clinical scenarios where these drugs can be used
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370(26):2467-77. DOI: https://doi.org/10.1056/NEJMoa1311376
Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478-86. DOI: https://doi.org/10.1056/NEJMoa1313600
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. DOI: https://doi.org/10.7326/0003-4819-146-12-200706190-00007